Fig 1.
Flow Chart of Study Cohort Enrollment.
Patients who received treatments with warfarin or any antiplatelet agent, including aspirin and clopidogrel, were excluded from the study population. A total of 190,210 patients were finally enrolled in the study cohort with 17,595 males with CHA2DS2-VASc score of 1 and 9,926 females with CHA2DS2-VASc score of 2. Among the 17,595 male patients, there were 3,092, 9,469, and 5,034 patients in the age groups of 20 to 49, 50 to 64, and 65 to 74 years of age, respectively. Among the 9,926 female patients, there were 1,290, 5,983, and 2,653 patients in the age groups of 20 to 49, 50 to 64, and 65 to 74 years of age, respectively. There were other 10,435 males with CHA2DS2-VASc score of 0 and 5,984 females with CHA2DS2-VASc score of 1 used as the reference group, respectively. AF = atrial fibrillation; CHA2DS2-VASc = heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65 to 74 years, female.
Table 1.
AnnuaI Risk of Ischemic thromboembolism by CHA2DS2-VASc Score among AF patients without anticoagulants.
Table 2.
AnnuaI Risk of Ischemic Thromboembolism Stratified by CHA2DS2-VASc Score, Gender, and Age among AF patients without anticoagulants.
Table 3.
Baseline Characteristics for AF Patients with One Additional Risk Factor of CHA2DS2-VASc Score*.
Fig 2.
Kaplan-Meier Survival Curves in AF patients with One Additional Risk Factor of CHA2DS2-VASc Score.
A. Cumulative survival curves in male patients with CHA2DS2-VASc Score of 1 in the age groups of 20 to 49, 50 to 64, and 65 to 74 years of age, respectively. There is no difference of the cumulative risk of ischemic thromboembolism between male AF patients with CHA2DS2-VASc score of 1 for 20 to 49 years of age and overall patients with CHA2DS2-VASc score of 0. B. Cumulative survival curves in female patients with CHA2DS2-VASc Score of 2 in the age groups of 20 to 49, 50 to 64, and 65 to 74 years of age, respectively. Young female patient with CHA2DS2-VASc score of 2 and 20 to 49 years of age showed significantly higher cumulative risk of clincial event as compared with overall female patients with CHA2DS2-VASc score of 1.
Table 4.
Risk of Ischemic Thromboembolism in AF Patients with One Additional Risk Factor of CHA2DS2-VASc Score*.